[1]Barrington S，Scarsbrook A．Evidence Based Indications for the Use of PET-CT in the United Kingdom 2012．London：The Royal College of Physicians and The Royal College of Radiologists，2012．

[2]NCCN clinical practice guidelines in oncology（NCCN guidelines ^®）Head and Neck cancer Version2．2013 NCCN．org．

[3]NCCN clinical practice guidelines in oncology ^TM头颈部肿瘤临床实践指南（中国版）．2010年．（源自英文版V．1．2010）．

[4]Chang MC，Chen JH，Liang JA，et al．Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma：a systematic review and meta-analysis．Eur J Radiol，2013，82（2）：366-373．

[5]Hung TM，Wang HM，Kang CJ，et al．Pretreatmen（18）F-FDG PET standardized uptake value of primary tumor and necklymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma．Oral Oncol，2013，49（2）：169-174．

[6]Tang LQ，Chen QY，Fan W，et al．Prospective study of tailoring whole-body dual-modality [18F] fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging．J Clin Oncol，2013，31（23）：2861-2869．

[7]Boellaard R，Delgado-Bolton R，Oyen WJ，et al．FDG PET/CT：EANM procedure guidelines for tumour imaging：version 2.0．Eur J Nucl Med Mol Imaging，2015，42（2）：328-354．

[8]Zheng XK，Chen LH，Wang QS，et al．Influence of [18F]fluorodeoxyglucose positron emission tomography on salvage treatment decision making for locally persistent nasopharyngeal carcinoma．Int J Radiat Oncol Biol Phys，2006，65（4）：1020-1025．

[9]Zheng XK，Chen LH，Wang QS，et al．Influence of FDG-PET on computed tomography-based radiotherapy planning for locally recurrent nasopharyngeal carcinoma．Int J Radiat Oncol Biol Phys，2007，69（5）：1381-1388．